why choose us

300×250 Ad Slot

Drug FDA Status

Showing 144 of 144 result(s) (Page 15 of 15)
Drug Name: Orserdu

Active Ingredient: elacestrant

Approval Date: 2023-01-27

Description: To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Drug Trials Snapshot

Drug Name: Jaypirca

Active Ingredient: pirtobrutinib

Approval Date: 2023-01-27

Description: To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor
Drug Trials Snapshot

Drug Name: Brenzavvy

Active Ingredient: bexagliflozin

Approval Date: 2023-01-20

Description: To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
Drug Trials Snapshot

Drug Name: Leqembi

Active Ingredient: lecanemab-irmb

Approval Date: 2023-01-06

Description: To treat Alzheimer's disease
Press Release

300×250 Ad Slot